Ansa Biotechnologies Raises $54.4M in Series B to Scale US DNA Synthesis Manufacturing
Ansa Biotechnologies closed a $54.4 million Series B financing round, consisting of $45.2 million raised and an additional $9.2 million in secured commitments, making the round oversubscribed1235.
Cerberus Ventures led the round, with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, AIM13, Fall Line Capital, and Black Opal Ventures12.
The funding will allow Ansa to expand its US-based DNA synthesis manufacturing capacity and improve customer experience12.
New board members from Cerberus Ventures and Fall Line Capital joined, bringing strategic and technical expertise to support Ansa's long-term goals2.
Ansa’s technology focuses on enzymatic DNA synthesis, aiming to accelerate innovation in fields such as medicine, agriculture, and industrial biotech by providing fast, accurate gene-length DNA molecules12.
The company claims its approach overcomes bottlenecks of traditional DNA synthesis and aspires to shift the industry from reading genomes to writing them12.
Sources:
1. https://www.fundz.net/fundings/ansa-biotechnologies-funding-round-series-b-c7d3d6
2. https://www.biospace.com/press-releases/ansa-biotechnologies-secures-54-4-million-in-series-b-financing-to-redefine-how-scientists-access-synthetic-dna-with-industrys-first-guaranteed-on-time-service